drugset / Trial / NCT00603642

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

NCT00603642

Phase 3 Completed 34 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of AMG 531 compared with placebo in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic purpura (ITP) .

Timeline

Start
2007-10-01
Primary completion
2009-04-13
Completion
2009-04-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Romiplostim Peptide Subcutaneous